Synthesis and evaluation as PDE4 inhibitors of pyrimidine‐2,4‐dione derivatives

A series of nitraquazone analogs with a pyrimidindione core was synthesized and tested for inhibitory activity on PDE4, selectivity versus PDE3 and PDE5 and for affinity towards the rolipram high‐affinity binding site (HARBS). The 5‐anilino derivatives 13–18 showed the best profile combining appreciable PDE4 inhibitory activity (IC50 = 5–14 µM) with a good selectivity toward PDE3 and PDE5. The same compounds demonstrate low affinity for the HARBS site with IC50 values of 12–69 µM (IC50 for Rolipram = 3.6 nM). Drug Dev Res 72: 274–288, 2011. © 2010 Wiley‐Liss, Inc.

[1]  Dongmei Wang,et al.  A Comparison of Phenylboronic Acid and Phenyltrimethyltin in the Palladium‐Catalyzed Arylation of 1,5‐Dialkylimidazoles. , 2010 .

[2]  P. Fossa,et al.  Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site. , 2007, Journal of medicinal chemistry.

[3]  John B. Cheng,et al.  SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. , 2007, Journal of medicinal chemistry.

[4]  V. D. Piaz,et al.  Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors , 2007, Journal of enzyme inhibition and medicinal chemistry.

[5]  V. Dal Piaz,et al.  Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors. , 2006, Life sciences.

[6]  Sarah B Karish,et al.  The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor , 2006, The Annals of pharmacotherapy.

[7]  C. Lugnier.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. , 2006, Pharmacology & therapeutics.

[8]  K. Julienne,et al.  Straightforward Pyrimidine Ring Construction: A Versatile Tool for the Synthesis of Nucleobase and Nucleoside Analogues , 2006 .

[9]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[10]  M. Mata,et al.  Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells , 2005, Thorax.

[11]  B. Lipworth.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease , 2005, The Lancet.

[12]  J. Traber,et al.  TVX 2706 — a new phosphodiesterase inhibitor with antiinflammatory action Biochemical characterization , 1984, Agents and Actions.

[13]  M. Burnet,et al.  CC-10004 . , 2005, Current opinion in investigational drugs.

[14]  J R Prous,et al.  Gateways to clinical trials. , 2005, Methods and findings in experimental and clinical pharmacology.

[15]  Domenico Spina,et al.  The potential of PDE4 inhibitors in respiratory disease. , 2004, Current drug targets. Inflammation and allergy.

[16]  T. Olsson,et al.  Polymer-supported copper complex for C-N and C-O cross-coupling reactions with aryl boronic acids. , 2004, Organic letters.

[17]  J. O'Donnell,et al.  Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus , 2004, Neuropsychopharmacology.

[18]  L. Favot,et al.  Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4 , 2004, Thrombosis and Haemostasis.

[19]  M. Giorgi,et al.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. , 2004, Endocrinology.

[20]  J. O'Donnell,et al.  Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). , 2004, Trends in pharmacological sciences.

[21]  R. Batey,et al.  Ligand- and base-free copper(II)-catalyzed C-N bond formation: cross-coupling reactions of organoboron compounds with aliphatic amines and anilines. , 2003, Organic letters.

[22]  M. Streiff,et al.  Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. , 2002, Blood.

[23]  S. Uhlig,et al.  Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  M. Fresno,et al.  Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[25]  M. Gütschow,et al.  Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro. , 2001, Bioorganic & medicinal chemistry.

[26]  A. Hatzelmann,et al.  Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE 4 Inhibitor Roflumilast in Vitro , 2001 .

[27]  M. Houslay,et al.  PDE4 cAMP-specific phosphodiesterases. , 2001, Progress in nucleic acid research and molecular biology.

[28]  M. Giovannoni,et al.  Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. , 2000, European journal of medicinal chemistry.

[29]  M. Houslay,et al.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. , 2000, The Biochemical journal.

[30]  L. Corral,et al.  Thalidomide analogs and PDE4 inhibition. , 1998, Bioorganic & medicinal chemistry letters.

[31]  V. D. Piaz,et al.  Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies , 1998 .

[32]  S. Christensen,et al.  1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. , 1998, Journal of medicinal chemistry.

[33]  S. Christensen,et al.  SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. , 1998, The Journal of pharmacology and experimental therapeutics.

[34]  M. Houslay,et al.  The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.

[35]  A. Fowler,et al.  OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. , 1997, The Journal of surgical research.

[36]  M. Giovannoni,et al.  Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. , 1997, Journal of medicinal chemistry.

[37]  J. Souness,et al.  Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. , 1997, Cellular signalling.

[38]  C. Schudt,et al.  2 – Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods , 1996 .

[39]  C. Lugnier,et al.  Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases , 1995 .

[40]  P. Barnes,et al.  Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. , 1995, Molecular pharmacology.

[41]  Dongmei Wang,et al.  A comparison of phenylboronic acid and phenyltrimethyltin in the palladium‐catalyzed arylation of 1,5‐dialkylimidazoles , 1994 .

[42]  K. A. Joergensen,et al.  Selective Oxidative Halogenation of Uracils. , 1994 .

[43]  J M O'Donnell,et al.  Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. , 1993, The Journal of pharmacology and experimental therapeutics.

[44]  T. Torphy,et al.  Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. , 1992, The Journal of pharmacology and experimental therapeutics.

[45]  M. Brezinski,et al.  Stereospecific binding of the antidepressant rolipram to brain protein structures. , 1986, European journal of pharmacology.

[46]  I. Winckelmann,et al.  Improved one-step procedure for the preparation of 1-substituted and 1,3-disubstituted uracils and 2-thiouracils , 1986 .

[47]  R. Colman,et al.  Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. , 1984, Biochemistry.

[48]  D. Priest,et al.  A sensitive assay employing a solid-phase metal chelator to estimate rates of iron accumulation by ferritin. , 1982, Analytical biochemistry.

[49]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[50]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.